Compare RNGR & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNGR | BBOT |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.2M | 442.6M |
| IPO Year | 2017 | 2024 |
| Metric | RNGR | BBOT |
|---|---|---|
| Price | $14.68 | $2.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $18.67 | ★ $24.55 |
| AVG Volume (30 Days) | 132.7K | ★ 536.1K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | N/A | ★ 99.93 |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.98 | N/A |
| Revenue Next Year | $1.46 | N/A |
| P/E Ratio | $120.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.88 | $2.86 |
| 52 Week High | $18.82 | $14.87 |
| Indicator | RNGR | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 15.24 |
| Support Level | $14.62 | N/A |
| Resistance Level | $16.42 | $9.36 |
| Average True Range (ATR) | 0.44 | 0.24 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 29.00 | 2.99 |
Ranger Energy Services Inc offers high specification mobile rig well services, cased hole wireline services, and ancillary services in the U.S. oil and gas industry. Its services facilitate operations throughout the lifecycle of a well, including the completion, production, maintenance, intervention, workover, and abandonment phases. The company's reportable segments are: High Specification Rigs, Wireline Services, Processing Solutions and Ancillary Services. Maximum revenue is generated from the High Specification Rigs segment, which offers high specification well service rigs and complementary equipment and services to facilitate operations throughout the lifecycle of a well. The high specification rig services consist of well completion support, workovers, and well maintenance services.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.